Skip to main content

Eltrombopag (Revolade) tablet Online| Blueberry pharmaceuticals

ELTROMBOPAG

Eltrombopag drug may be needed as part of combination therapy. Thereby drug may need to take it with other medications. Eltrombopag is a prescription drug which is used under the guidance of the doctor

INDICATION

Eltrombopag is mainly indicated for the treatment of patients having Reduced platelet levels due to chronic immune thrombocytopenia
Eltrombopag is mainly indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection Eltrombopag is mainly indicated for the treatment of patients having Severe Aplastic Anemia

1. First line treatment of severe Aplastic Anemia
2. Treatment of refractory severe Aplastic Anemia

MECHANISM OF ACTION

Eltrombopag exist in a class of drugs called thrombopoietin (TPO) receptor agonists. Classification of drugs is an association of medications which work in a similar way. These drugs are often used to treat similar conditions.

DOSAGE AND ADMINISTRATION

Chronic Hepatitis C-associated Thrombocytopenia:
The recommended dose: 25 mg PO qDay
The dose is Adjust in 25 mg accretion q2weeks PRN to attain target Pelt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
Severe Aplastic Anemia

COMMON SIDE EFFECTS

• nausea
• fever
• weakness
• pain in head
• cough
• decreased appetite
• flu
• low red blood cells
• diarrhea

PRECAUTIONS

If the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse. Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increase the risk of death. If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.

DRUG-DRUG INTERACTION

These drug sezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan interaction with Eltrombopag will increase of side effects. hence the doctor may reduce your dosage of these drugs if required.

PREGNANCY

Pregnancy category is C
Animal studies reveal risk and human studies not available or neither animal nor human studies done.Use the Eltrombopag with caution if asset outweigh risks

LACTATION

The drug is not recommended during breastfeeding.

STORAGE

Store at room temperature 20°C and 25°C Discard the left-out medicine if not used within 30 minutes.

MISSED DOSE

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

info@blueberrypharma.com

PHONE:

+91-97890 77748

VISIT US:

blueberrypharma.com/eltrombopag.php
Labels:

Comments

Post a Comment

Popular posts from this blog

EVEROLIMUS TABLETS COST IN INDIA

EVEROLIMUS DESCRIPTION  Everolimus  belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor).  Everolimus  is an immunosuppressive macrolide. EVEROLIMUS USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with  Everolimus .  Everolimus  is used in the advanced stage of breast cancer. Neuroendocrine tumors  Everolimus involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer Patient treating with  Everolimus  after the failure of treatment with Sunitinib or Sorafenib.  Everolimus  also used in the condition of Heart, liver, kidney transplantation, Waldenstrom macroglobulinemia, Other carcinoid tumors Brand: Evertor Strength: 10mg Ingredient: Everolimus Company Name: Biocon Tab Count: 10 Tablets MECHANISM OF ACTION Everolimus  is the prohibition o
1 comment
Read more

Nivolumab (Opdivo & Opdyta) Injection Online | Blueberry pharmaceuticals

NIVOLUMAB Nivolumab belongs to a group of cancer drugs known as monoclonal antibodies. Nivolumab is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. Nivolumab is a prescription drug which is used under the supervision of a doctor INDICATION Nivolumab is indicated for the treatment of patients having Melanoma. Nivolumab is indicated for the treatment of patients having Non-Small Cell Lung Cancer. Nivolumab is indicated for the treatment of patients having Kidney (Renal Cell) Cancer. MECHANISM OF ACTION Nivolumab prohibits the molecule activity called PD-1, and it is a protein which prevents T cells from recognizing and attacking inflamed tissues and cancer cells. PD-1 can deceit the immune system into overlooking melanoma cells as normal cells. DOSAGE AND ADMINISTRATION Nivolumab recommended dosage for unresectable or metastatic melanoma : As a single
Post a Comment
Read more

Rapact 10 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTION Rapact 10mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Rapact 10mg is an immunosuppressive macrolide. USED FOR Breast cancer  Patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Rapact. Rapact 10mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Rapact 10mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  patient treating with Rapact 10mg after the failure of treatment with Sunitinib or Sorafenib. Rapact 10mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Rapact is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Rapact bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex
Post a Comment
Read more